Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Back to our regularly scheduled program

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Jan 06, 2024 6:29am

160 Views

Post# 35813579

RE:RE:Back to our regularly scheduled program

I hear ya.l

Although 3X as a Price to Sales Ratio still seems a bit llight to me considering :

1. CTSO once was trading well over 10X on a P/S ratio basis when people actually thought that it worked ( ie before latest study results)

2. PMX would be the first new FDA approved treatment for ESS (assuming confirmed in 3b) in decades - with exclusivity and protections. In essence it would be the new SOC for NA

3. Possible expanded label use

4. Worldwide rights to the all important companion diagnostic. See personalized medicine.

5. Partnership with the largest distributor of medical equipment to US hospitals ( CTSO had no FdA approved access to the all important US market )